Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SOPHiA GENETICS ( (SOPH) ) has issued an update.
On March 3, 2026, SOPHiA GENETICS reported that fourth-quarter 2025 revenue rose 22% year over year to $21.7 million, while full-year 2025 revenue grew 19% to $77.3 million, with adjusted gross margin improving to 74.2% despite higher data volumes. The company’s IFRS net loss widened to $79.0 million for 2025 and adjusted EBITDA loss to $41.5 million, but management highlighted growing platform scale, record 391,000+ analyses, 528 core genomics customers, and stronger U.S. and liquid biopsy traction as key drivers toward improved operating leverage.
The company signed a record 124 new core genomics customers in 2025, secured two large U.S. integrated health systems expected to add about 60,000 analyses annually starting in the second half of 2026, and expanded collaborations with major cancer centers and biopharma partners. Supported by a higher-margin, cloud-native model, new credit capacity and ATM proceeds, SOPHiA GENETICS reaffirmed its 2026 outlook for 20–22% revenue growth to $92–94 million and a reduced adjusted EBITDA loss of $29–32 million, signaling a path toward breakeven by end-2026 and positive adjusted EBITDA in the second half of 2027.
The most recent analyst rating on (SOPH) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on SOPHiA GENETICS stock, see the SOPH Stock Forecast page.
Spark’s Take on SOPH Stock
According to Spark, TipRanks’ AI Analyst, SOPH is a Neutral.
SOPHiA GENETICS’ overall stock score is primarily influenced by its financial performance challenges, including profitability and cash flow issues. While technical analysis shows positive momentum, valuation concerns due to ongoing losses weigh heavily. The earnings call highlights strong growth and strategic initiatives, but these are not enough to offset the financial challenges.
To see Spark’s full report on SOPH stock, click here.
More about SOPHiA GENETICS
SOPHiA GENETICS is a Switzerland- and U.S.-based health‑tech company specializing in AI-driven precision medicine. Its cloud-native SOPHiA DDM platform enables genomic and multimodal data analysis for hospitals, laboratories, and biopharma partners, with a growing focus on oncology applications and the U.S. healthcare market.
Average Trading Volume: 182,108
Technical Sentiment Signal: Buy
Current Market Cap: $313.5M
For a thorough assessment of SOPH stock, go to TipRanks’ Stock Analysis page.